99 results on '"Benghanem Gharbi, M"'
Search Results
2. Obesity and kidney disease: Hidden consequences of the epidemic
- Author
-
Kovesdy, CP, Furth, S, Zoccali, C, Tao Li, PK, García-García, G, Benghanem-Gharbi, M, Bollaert, R, Dupuis, S, Erk, T, Kalantar-Zadeh, K, Kovesdy, C, Osafo, C, Riella, MC, and Zakharova, E
- Abstract
Obesity has become a worldwide epidemic, and its prevalence has been projected to grow by 40% in the next decade. This increasing prevalence has implications for the risk of diabetes, cardiovascular disease and also for Chronic Kidney Disease. A high body mass index is one of the strongest risk factors for new-onset Chronic Kidney Disease. In individuals affected by obesity, a compensatory hyperfiltration occurs to meet the heightened metabolic demands of the increased body weight. The increase in intraglomerular pressure can damage the kidneys and raise the risk of developing Chronic Kidney Disease in the long-term. The incidence of obesityrelated glomerulopathy has increased ten-fold in recent years. Obesity has also been shown to be a risk factor for nephrolithiasis, and for a number of malignancies including kidney cancer. This year the World Kidney Day promotes education on the harmful consequences of obesity and its association with kidney disease, advocating healthy lifestyle and health policy measures that makes preventive behaviors an affordable option.
- Published
- 2017
3. WCN23-0442 MICROBIOLOGICAL PROFILE OF CATHETER AND ARTERIOVENOUS FISTULA INFECTIONS IN CHRONIC HAEMODIALYSIS: EXPERIENCE OF THE IBN ROCHD UNIVERSITY HOSPITAL IN CASABLANCA
- Author
-
AZRIA, S., primary, Chaanoun, K., additional, El Atiqi, Y., additional, Zamd, M., additional, Mtioui, N., additional, El Khayat, S.S., additional, Medkouri, G., additional, Benghanem Gharbi, M., additional, and Boujmad, A., additional
- Published
- 2023
- Full Text
- View/download PDF
4. WCN23-0435 UREMIC PERICARDITIS IN CHRONIC END-STAGE RENAL DISEASE: EXPERIENCE OF THE IBN ROCHD UNIVERSITY HOSPITAL
- Author
-
AZRIA, S., primary, Chaanoun, K., additional, Maazouzi, C., additional, Mtioui, N., additional, El Khayat, S.S., additional, Zamd, M., additional, Medkouri, G., additional, Benghanem Gharbi, M., additional, Belhakim, M., additional, Ettagmouti, Y., additional, Njie, M., additional, and Habbal, R., additional
- Published
- 2023
- Full Text
- View/download PDF
5. Impact de l’hémodialyse sur la pression intraoculaire
- Author
-
Azria, S., primary, Chaanoun, K., additional, El Atiqi, Y., additional, Zamd, M., additional, Mtioui, N., additional, El Khayat, S.S., additional, Medkouri, G., additional, Benghanem Gharbi, M., additional, and Chiguer, S., additional
- Published
- 2022
- Full Text
- View/download PDF
6. La dialyse aggrave-t-elle les troubles anxiodépressifs chez l’insuffisant rénal chronique ?
- Author
-
Chaanoun, K., primary, Azria, S., additional, Cheikh, S., additional, Zamd, M., additional, Mtioui, N., additional, El Khayat, S.S., additional, Medkouri, G., additional, and Benghanem Gharbi, M., additional
- Published
- 2022
- Full Text
- View/download PDF
7. Le pronostic fonctionnel rénal en transplantation rénale pédiatrique : expérience du CHU Ibn Rochd de Casablanca
- Author
-
Chaanoun, K., primary, Azria, S., additional, El Atiqi, Y., additional, Mtioui, N., additional, Medkouri, G., additional, El Khayat, S.S., additional, Zamd, M., additional, and Benghanem Gharbi, M., additional
- Published
- 2022
- Full Text
- View/download PDF
8. Current status of health systems financing and oversight for end-stage kidney disease care: A cross-sectional global survey.
- Author
-
Yeung E., Bello A.K., Levin A., Lunney M., Osman M.A., Ye F., Ashuntantang G., Bellorin-Font E., Benghanem Gharbi M., Davison S., Ghnaimat M., Harden P., Jha V., Kalantar-Zadeh K., Kerr P., Klarenbach S., Kovesdy C., Luyckx V., Neuen B., O'Donoghue D., Ossareh S., Perl J., Ur Rashid H., Rondeau E., See E., Saad S., Sola L., Tchokhonelidze I., Tesar V., Tungsanga K., Turan Kazancioglu R., Wang A.Y.-M., Wiebe N., Yang C.-W., Zemchenkov A., Zhao M., Jager K.J., Caskey F., Perkovic V., Jindal K., Okpechi I.G., Tonelli M., Feehally J., Harris D.C.H., Johnson D., Yeung E., Bello A.K., Levin A., Lunney M., Osman M.A., Ye F., Ashuntantang G., Bellorin-Font E., Benghanem Gharbi M., Davison S., Ghnaimat M., Harden P., Jha V., Kalantar-Zadeh K., Kerr P., Klarenbach S., Kovesdy C., Luyckx V., Neuen B., O'Donoghue D., Ossareh S., Perl J., Ur Rashid H., Rondeau E., See E., Saad S., Sola L., Tchokhonelidze I., Tesar V., Tungsanga K., Turan Kazancioglu R., Wang A.Y.-M., Wiebe N., Yang C.-W., Zemchenkov A., Zhao M., Jager K.J., Caskey F., Perkovic V., Jindal K., Okpechi I.G., Tonelli M., Feehally J., Harris D.C.H., and Johnson D.
- Abstract
The Global Kidney Health Atlas (GKHA) is a multinational, cross-sectional survey designed to assess the current capacity for kidney care across all world regions. The 2017 GKHA involved 125 countries and identified significant gaps in oversight, funding and infrastructure to support care for patients with kidney disease, especially in lower-middle-income countries. Here, we report results from the survey for the second iteration of the GKHA conducted in 2018, which included specific questions about health financing and oversight of end-stage kidney disease (ESKD) care worldwide. A cross-sectional global survey. Key stakeholders from 182 countries were invited to participate. Of those, stakeholders from 160 countries participated and were included. Primary outcomes included cost of kidney replacement therapy (KRT), funding for dialysis and transplantation, funding for conservative kidney management, extent of universal health coverage, out-of-pocket costs for KRT, within-country variability in ESKD care delivery and oversight systems for ESKD care. Outcomes were determined from a combination of desk research and input from key stakeholders in participating countries. 160 countries (covering 98% of the world's population) responded to the survey. Economic factors were identified as the top barrier to optimal ESKD care in 99 countries (64%). Full public funding for KRT was more common than for conservative kidney management (43% vs 28%). Among countries that provided at least some public coverage for KRT, 75% covered all citizens. Within-country variation in ESKD care delivery was reported in 40% of countries. Oversight of ESKD care was present in all high-income countries but was absent in 13% of low-income, 3% of lower-middle-income, and 10% of upper-middle-income countries. Significant gaps and variability exist in the public funding and oversight of ESKD care in many countries, particularly for those in low-income and lower-middle-income countries.Copyright © Autho
- Published
- 2021
9. Availability, coverage, and scope of health information systems for kidney care across world countries and regions.
- Author
-
Kazancioglu R.T., Rashid H.U., Rondeau E., Syed S., Sola L., Tchokhonelidze I., Tesar V., Tungsanga K., Wang A.Y.-M., Johnson D.W., Harris D.C., Feehally J., Tonelli M., Okpechi I.G., Jindal K.K., Perkovic V., Caskey F., Jager K.J., Zhao M.-H., Zemchenkov A., Yang C.-W., See E.J., Bello A.K., Levin A., Lunney M., Osman M.A., Ye F., Ashuntantang G.E., Bellorin-Font E., Benghanem Gharbi M., Davison S., Ghnaimat M., Harden P., Htay H., Jha V., Kalantar-Zadeh K., Kerr P.G., Klarenbach S., Kovesdy C.P., Luyckx V., Neuen B., O'Donoghue D., Ossareh S., Perl J., Kazancioglu R.T., Rashid H.U., Rondeau E., Syed S., Sola L., Tchokhonelidze I., Tesar V., Tungsanga K., Wang A.Y.-M., Johnson D.W., Harris D.C., Feehally J., Tonelli M., Okpechi I.G., Jindal K.K., Perkovic V., Caskey F., Jager K.J., Zhao M.-H., Zemchenkov A., Yang C.-W., See E.J., Bello A.K., Levin A., Lunney M., Osman M.A., Ye F., Ashuntantang G.E., Bellorin-Font E., Benghanem Gharbi M., Davison S., Ghnaimat M., Harden P., Htay H., Jha V., Kalantar-Zadeh K., Kerr P.G., Klarenbach S., Kovesdy C.P., Luyckx V., Neuen B., O'Donoghue D., Ossareh S., and Perl J.
- Abstract
BACKGROUND: Health information systems (HIS) are fundamental tools for the surveillance of health services, estimation of disease burden and prioritization of health resources. Several gaps in the availability of HIS for kidney disease were highlighted by the first iteration of the Global Kidney Health Atlas. METHOD(S): As part of its second iteration, the International Society of Nephrology conducted a cross-sectional global survey between July and October 2018 to explore the coverage and scope of HIS for kidney disease, with a focus on kidney replacement therapy (KRT). RESULT(S): Out of a total of 182 invited countries, 154 countries responded to questions on HIS (85% response rate). KRT registries were available in almost all high-income countries, but few low-income countries, while registries for non-dialysis chronic kidney disease (CKD) or acute kidney injury (AKI) were rare. Registries in high-income countries tended to be national, in contrast to registries in low-income countries, which often operated at local or regional levels. Although cause of end-stage kidney disease, modality of KRT and source of kidney transplant donors were frequently reported, few countries collected data on patient-reported outcome measures and only half of low-income countries recorded process-based measures. Almost no countries had programs to detect AKI and practices to identify CKD-targeted individuals with diabetes, hypertension and cardiovascular disease, rather than members of high-risk ethnic groups. CONCLUSION(S): These findings confirm significant heterogeneity in the global availability of HIS for kidney disease and highlight important gaps in their coverage and scope, especially in low-income countries and across the domains of AKI, non-dialysis CKD, patient-reported outcomes, process-based measures and quality indicators for KRT service delivery.Copyright © The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
- Published
- 2021
10. Current status of health systems financing and oversight for end-stage kidney disease care: a cross-sectional global survey
- Author
-
Yeung, E, Bello, AK, Levin, A, Lunney, M, Osman, MA, Ye, F, Ashuntantang, G, Bellorin-Font, E, Benghanem Gharbi, M, Davison, S, Ghnaimat, M, Harden, P, Jha, V, Kalantar-Zadeh, K, Kerr, P, Klarenbach, S, Kovesdy, C, Luyckx, V, Neuen, B, O'Donoghue, D, Ossareh, S, Perl, J, Ur Rashid, H, Rondeau, E, See, E, Saad, S, Sola, L, Tchokhonelidze, I, Tesar, V, Tungsanga, K, Turan Kazancioglu, R, Wang, AY-M, Wiebe, N, Yang, C-W, Zemchenkov, A, Zhao, M, Jager, KJ, Caskey, F, Perkovic, V, Jindal, K, Okpechi, IG, Tonelli, M, Feehally, J, Harris, DCH, Johnson, D, Yeung, E, Bello, AK, Levin, A, Lunney, M, Osman, MA, Ye, F, Ashuntantang, G, Bellorin-Font, E, Benghanem Gharbi, M, Davison, S, Ghnaimat, M, Harden, P, Jha, V, Kalantar-Zadeh, K, Kerr, P, Klarenbach, S, Kovesdy, C, Luyckx, V, Neuen, B, O'Donoghue, D, Ossareh, S, Perl, J, Ur Rashid, H, Rondeau, E, See, E, Saad, S, Sola, L, Tchokhonelidze, I, Tesar, V, Tungsanga, K, Turan Kazancioglu, R, Wang, AY-M, Wiebe, N, Yang, C-W, Zemchenkov, A, Zhao, M, Jager, KJ, Caskey, F, Perkovic, V, Jindal, K, Okpechi, IG, Tonelli, M, Feehally, J, Harris, DCH, and Johnson, D
- Abstract
OBJECTIVES: The Global Kidney Health Atlas (GKHA) is a multinational, cross-sectional survey designed to assess the current capacity for kidney care across all world regions. The 2017 GKHA involved 125 countries and identified significant gaps in oversight, funding and infrastructure to support care for patients with kidney disease, especially in lower-middle-income countries. Here, we report results from the survey for the second iteration of the GKHA conducted in 2018, which included specific questions about health financing and oversight of end-stage kidney disease (ESKD) care worldwide. SETTING: A cross-sectional global survey. PARTICIPANTS: Key stakeholders from 182 countries were invited to participate. Of those, stakeholders from 160 countries participated and were included. PRIMARY OUTCOMES: Primary outcomes included cost of kidney replacement therapy (KRT), funding for dialysis and transplantation, funding for conservative kidney management, extent of universal health coverage, out-of-pocket costs for KRT, within-country variability in ESKD care delivery and oversight systems for ESKD care. Outcomes were determined from a combination of desk research and input from key stakeholders in participating countries. RESULTS: 160 countries (covering 98% of the world's population) responded to the survey. Economic factors were identified as the top barrier to optimal ESKD care in 99 countries (64%). Full public funding for KRT was more common than for conservative kidney management (43% vs 28%). Among countries that provided at least some public coverage for KRT, 75% covered all citizens. Within-country variation in ESKD care delivery was reported in 40% of countries. Oversight of ESKD care was present in all high-income countries but was absent in 13% of low-income, 3% of lower-middle-income, and 10% of upper-middle-income countries. CONCLUSION: Significant gaps and variability exist in the public funding and oversight of ESKD care in many countries, particularly f
- Published
- 2021
11. SAT-359 BECOMING LIVING-RELATED DONORS: RISK OF CHRONIC KIDNEY DISEASE AND HYPERTENSION
- Author
-
Filali Khattabi, Z., primary, Amayoud, H., additional, Mtioui Chkairi, N., additional, Zamd, M., additional, El Khayat, S.S., additional, Medkouri, G., additional, Benghanem Gharbi, M., additional, and Ramdani, B., additional
- Published
- 2020
- Full Text
- View/download PDF
12. Troubles sexuels chez 78 hémodialysés chroniques marocains de sexe masculin : étude clinique et endocrinienne
- Author
-
Zamd, M., Farh, M., Hbid, O., Zabari, M., Benghanem Gharbi, M., Ramdani, B., Zaïd, D., El Abbadi, N., Lalaoui, K., Belhouari, A., and Hassan Tahri, E.
- Published
- 2004
- Full Text
- View/download PDF
13. Prise en charge de la douleur à la ponction de la fistule artério-veineuse : cryoantalgie vs. lidocaine/prilocaîne
- Author
-
Filali Khattabi, Z., primary, El Badaoui, S., additional, Kortobi, L., additional, Mtioui Chkairi, N., additional, Zamd, M., additional, Medkouri, G., additional, Benghanem Gharbi, M., additional, Ramdani, B., additional, and El Khayat, S., additional
- Published
- 2019
- Full Text
- View/download PDF
14. Status of care for end stage kidney disease in countries and regions worldwide: International cross sectional survey.
- Author
-
Rashid H.U., Klarenbach S., Kovesdy C.P., Luyckx V.A., Neuen B.L., O'Donoghue D., Ossareh S., Perl J., Rondeau E., Johnson D.W., Harris D.C., Feehally J., Tonelli M., Okpechi I.G., Jindal K.K., Perkovic V., Caskey F., Jager K.J., Zhao M.-H., Zemchenkov A., Yang C.-W., Wiebe N., Wang A.Y.-M., Turan Kazancioglu R., Tungsanga K., Tesar V., Tchokhonelidze I., Sola L., Saad S., See E., Bello A.K., Levin A., Lunney M., Osman M.A., Ye F., Ashuntantang G.E., Bellorin-Font E., Benghanem Gharbi M., Davison S.N., Ghnaimat M., Harden P., Htay H., Jha V., Kalantar-Zadeh K., Kerr P.G., Rashid H.U., Klarenbach S., Kovesdy C.P., Luyckx V.A., Neuen B.L., O'Donoghue D., Ossareh S., Perl J., Rondeau E., Johnson D.W., Harris D.C., Feehally J., Tonelli M., Okpechi I.G., Jindal K.K., Perkovic V., Caskey F., Jager K.J., Zhao M.-H., Zemchenkov A., Yang C.-W., Wiebe N., Wang A.Y.-M., Turan Kazancioglu R., Tungsanga K., Tesar V., Tchokhonelidze I., Sola L., Saad S., See E., Bello A.K., Levin A., Lunney M., Osman M.A., Ye F., Ashuntantang G.E., Bellorin-Font E., Benghanem Gharbi M., Davison S.N., Ghnaimat M., Harden P., Htay H., Jha V., Kalantar-Zadeh K., and Kerr P.G.
- Abstract
Objective To determine the global capacity (availability, accessibility, quality, and affordability) to deliver kidney replacement therapy (dialysis and transplantation) and conservative kidney management. Design International cross sectional survey. Setting International Society of Nephrology (ISN) survey of 182 countries from July to September 2018. Participants Key stakeholders identified by ISN's national and regional leaders. Main outcome measures Markers of national capacity to deliver core components of kidney replacement therapy and conservative kidney management. Results Responses were received from 160 (87.9%) of 182 countries, comprising 97.8% (7338.5 million of 7501.3 million) of the world's population. A wide variation was found in capacity and structures for kidney replacement therapy and conservative kidney management-namely, funding mechanisms, health workforce, service delivery, and available technologies. Information on the prevalence of treated end stage kidney disease was available in 91 (42%) of 218 countries worldwide. Estimates varied more than 800-fold from 4 to 3392 per million population. Rwanda was the only low income country to report data on the prevalence of treated disease; 5 (<10%) of 53 African countries reported these data. Of 159 countries, 102 (64%) provided public funding for kidney replacement therapy. Sixty eight (43%) of 159 countries charged no fees at the point of care delivery and 34 (21%) made some charge. Haemodialysis was reported as available in 156 (100%) of 156 countries, peritoneal dialysis in 119 (76%) of 156 countries, and kidney transplantation in 114 (74%) of 155 countries. Dialysis and kidney transplantation were available to more than 50% of patients in only 108 (70%) and 45 (29%) of 154 countries that offered these services, respectively. Conservative kidney management was available in 124 (81%) of 154 countries. Worldwide, the median number of nephrologists was 9.96 per million population, which varied with i
- Published
- 2019
15. Global overview of health systems oversight and financing for kidney care.
- Author
-
Ye F., Yang C.-W., Zemchenkov A., Levin A., Zhao M.-H., Bello A.K., Alrukhaimi M., Ashuntantang G.E., Bellorin-Font E., Benghanem Gharbi M., Braam B., Feehally J., Harris D.C., Jha V., Jindal K., Johnson D.W., Kalantar-Zadeh K., Kazancioglu R., Kerr P.G., Lunney M., Olanrewaju T.O., Osman M.A., Perl J., Rashid H.U., Rateb A., Rondeau E., Sakajiki A.M., Samimi A., Sola L., Tchokhonelidze I., Wiebe N., Ye F., Yang C.-W., Zemchenkov A., Levin A., Zhao M.-H., Bello A.K., Alrukhaimi M., Ashuntantang G.E., Bellorin-Font E., Benghanem Gharbi M., Braam B., Feehally J., Harris D.C., Jha V., Jindal K., Johnson D.W., Kalantar-Zadeh K., Kazancioglu R., Kerr P.G., Lunney M., Olanrewaju T.O., Osman M.A., Perl J., Rashid H.U., Rateb A., Rondeau E., Sakajiki A.M., Samimi A., Sola L., Tchokhonelidze I., and Wiebe N.
- Abstract
Reliable governance and health financing are critical to the abilities of health systems in different countries to sustainably meet the health needs of their peoples, including those with kidney disease. A comprehensive understanding of existing systems and infrastructure is therefore necessary to globally identify gaps in kidney care and prioritize areas for improvement. This multinational, cross-sectional survey, conducted by the ISN as part of the Global Kidney Health Atlas, examined the oversight, financing, and perceived quality of infrastructure for kidney care across the world. Overall, 125 countries, comprising 93% of the world's population, responded to the entire survey, with 122 countries responding to questions pertaining to this domain. National oversight of kidney care was most common in high-income countries while individual hospital oversight was most common in low-income countries. Parts of Africa and the Middle East appeared to have no organized oversight system. The proportion of countries in which health care system coverage for people with kidney disease was publicly funded and free varied for AKI (56%), nondialysis chronic kidney disease (40%), dialysis (63%), and kidney transplantation (57%), but was much less common in lower income countries, particularly Africa and Southeast Asia, which relied more heavily on private funding with out-of-pocket expenses for patients. Early detection and management of kidney disease were least likely to be covered by funding models. The perceived quality of health infrastructure supporting AKI and chronic kidney disease care was rated poor to extremely poor in none of the high-income countries but was rated poor to extremely poor in over 40% of low-income countries, particularly Africa. This study demonstrated significant gaps in oversight, funding, and infrastructure supporting health services caring for patients with kidney disease, especially in low- and middle-income countries.Copyright © 2017 Internationa
- Published
- 2018
16. Global access of patients with kidney disease to health technologies and medications: findings from the Global Kidney Health Atlas project.
- Author
-
Wiebe N., Sola L., Tchokhonelidze I., Tonelli M., Wirzba I., Yang C.-W., Ye F., Zemchenkov A., Zhao M.-H., Johnson D.W., Htay H., Alrukhaimi M., Ashuntantang G.E., Bello A.K., Bellorin-Font E., Benghanem Gharbi M., Braam B., Feehally J., Harris D.C., Jha V., Jindal K., Kalantar-Zadeh K., Kazancioglu R., Kerr P.G., Levin A., Lunney M., Okpechi I.G., Olah M.E., Olanrewaju T.O., Osman M.A., Parpia Y., Perl J., Qarni B., Rashid H.U., Rateb A., Rondeau E., Salako B.L., Wiebe N., Sola L., Tchokhonelidze I., Tonelli M., Wirzba I., Yang C.-W., Ye F., Zemchenkov A., Zhao M.-H., Johnson D.W., Htay H., Alrukhaimi M., Ashuntantang G.E., Bello A.K., Bellorin-Font E., Benghanem Gharbi M., Braam B., Feehally J., Harris D.C., Jha V., Jindal K., Kalantar-Zadeh K., Kazancioglu R., Kerr P.G., Levin A., Lunney M., Okpechi I.G., Olah M.E., Olanrewaju T.O., Osman M.A., Parpia Y., Perl J., Qarni B., Rashid H.U., Rateb A., Rondeau E., and Salako B.L.
- Abstract
Access to essential medications and health products is critical to effective management of kidney disease. Using data from the ISN Global Kidney Health Atlas multinational cross-sectional survey, global access of patients with kidney disease to essential medications and health products was examined. Overall, 125 countries participated, with 118 countries, composing 91.5% of the world's population, providing data on this domain. Most countries were unable to access eGFR and albuminuria in their primary care settings. Only one-third of low-income countries (LICs) were able to measure serum creatinine and none were able to access eGFR or quantify proteinuria. The ability to monitor diabetes mellitus through serum glucose and glycated hemoglobin measurements was suboptimal. Pathology services were rarely available in tertiary care in LICs (12%) and lower middle-income countries (45%). While acute and chronic hemodialysis services were available in almost all countries, acute and chronic peritoneal dialysis services were rarely available in LICs (18% and 29%, respectively). Kidney transplantation was available in 79% of countries overall and in 12% of LICs. While over one-half of all countries publicly funded RRT and kidney medications with or without copayment, this was less common in LICs and lower middle-income countries. In conclusion, this study demonstrated significant gaps in services for kidney care and funding that were most apparent in LICs and lower middle-income countries.Copyright © 2017
- Published
- 2018
17. What we do and do not know about women and kidney diseases; Questions unanswered and answers unquestioned: Reflection on world kidney day and international woman's day
- Author
-
Piccoli, GB, Piccoli, GB, Alrukhaimi, M, Liu, ZH, Zakharova, E, Levin, A, Li, PKT, Garcia-Garcia, G, Benghanem-Gharbi, M, Kalantar-Zadeh, K, Kernahan, C, Kumaraswami, L, Saadi, G, Fox, L, Andreoli, S, Piccoli, GB, Piccoli, GB, Alrukhaimi, M, Liu, ZH, Zakharova, E, Levin, A, Li, PKT, Garcia-Garcia, G, Benghanem-Gharbi, M, Kalantar-Zadeh, K, Kernahan, C, Kumaraswami, L, Saadi, G, Fox, L, and Andreoli, S
- Abstract
Chronic Kidney Disease affects approximately 10% of the world's adult population: it is within the top 20 causes of death worldwide, and its impact on patients and their families can be devastating. World Kidney Day and International Women's Day in 2018 coincide, thus offering an opportunity to reflect on the importance of women's health and specifically their kidney health, on the community, and the next generations, as well as to strive to be more curious about the unique aspects of kidney disease in women so that we may apply those learnings more broadly. Girls and women, who make up approximately 50% of the world's population, are important contributors to society and their families. Gender differences continue to exist around the world in access to education, medical care, and participation in clinical studies. Pregnancy is a unique state for women, offering an opportunity for diagnosis of kidney disease, but also a state where acute and chronic kidney diseases may manifest, and which may impact future generations with respect to kidney health. There are various autoimmune and other conditions that are more likely to impact women with profound consequences for child bearing, and on the fetus. Women have different complications on dialysis than men, and are more likely to be donors than recipients of kidney transplants. In this editorial, we focus on what we do and do not know about women, kidney health, and kidney disease, and what we might learn in the future to improve outcomes worldwide.
- Published
- 2018
18. Granulomatosis with Polyangiitis in Patient with Crohn’s Disease
- Author
-
Mtioui N, Ramdani B, Bennani Guebessi N, Benghanem Gharbi M, Zmad Ma, Mohamed Ak, G. Medkouri, and Kheyat Ss
- Subjects
Pathology ,medicine.medical_specialty ,business.industry ,Crescentic glomerulonephritis ,Inflammation ,Glomerulonephritis ,Disease ,medicine.disease ,medicine ,Rapidly progressive glomerulonephritis ,In patient ,medicine.symptom ,business ,Granulomatosis with polyangiitis ,Organ system - Abstract
Granulomatosis with polyangiitis and Crohn’s disease are two distinct chronic inflammatory diseases that may involve various organ systems, including the alimentary tract and the oropharynx. In both diseases there is an association with different types of anti-neutrophil cytoplasmic antibodies. We describe a patient previously diagnosed with Crohn’s disease, presenting 20 years later with a rapidly progressive glomerulonephritis and histological evidence of crescentic glomerulonephritis and surrounded by severe interstitial inflammatory infiltrate, ultimately diagnosed as having granulomatosis with polyangiitis.
- Published
- 2017
- Full Text
- View/download PDF
19. P-058: Recovery of renal function in malignant hypertension patients on dialysis
- Author
-
Khalfaoui, M., primary, Mtioui, N., additional, Khayat, S.S., additional, Zamd, M.A., additional, Medkouri, G., additional, Benghanem Gharbi, M., additional, and Ramdani, B., additional
- Published
- 2015
- Full Text
- View/download PDF
20. Profil de la glomérulonéphrite membrano-proliférative : à propos de 26 cas
- Author
-
Khalfaoui, M.A., primary, Mtioui, N., additional, Elkheyat, S., additional, Zamd, M., additional, Medkouri, G., additional, Benghanem Gharbi, M., additional, and Ramdani, B., additional
- Published
- 2015
- Full Text
- View/download PDF
21. Évolution du taux d’anticorps anti-Hbs après vaccination contre l’hépatite B chez des patients atteints d’insuffisance rénale non dialysés
- Author
-
Khalfaoui, M.A., primary, Tahiri, A., additional, Mtioui, N., additional, Elkheyat, S., additional, Zamd, M., additional, Medkouri, G., additional, Benghanem Gharbi, M., additional, and Ramdani, B., additional
- Published
- 2015
- Full Text
- View/download PDF
22. Estimation des besoins en greffe rénale au Maroc
- Author
-
Boly, A., primary, Trabelsi, M.E.H., additional, Ramdani, B., additional, Bayahia, R., additional, Benghanem Gharbi, M., additional, Boucher, S., additional, El Berri, H., additional, Nejjari, C., additional, and Couchoud, C., additional
- Published
- 2014
- Full Text
- View/download PDF
23. Fractures pathologiques chez l’hémodialysé
- Author
-
Zenasni, N., primary, Noto-Kadou-Kaza, B., additional, Kanbouchi, F., additional, El Khayate, S., additional, Zamd, M., additional, Medkouri, G., additional, Benghanem Gharbi, M., additional, and Ramdani, B., additional
- Published
- 2014
- Full Text
- View/download PDF
24. Néphropathie lupique : éléments pronostiques à six mois
- Author
-
Kanbouchi, F., primary, Zenasni, N., additional, El. Khayate, S., additional, Zamd, M., additional, Medkouri, G., additional, Benghanem Gharbi, M., additional, and Ramdani, B., additional
- Published
- 2014
- Full Text
- View/download PDF
25. L’intervalle QTc en per-hémodialyse
- Author
-
Zenasni, N., primary, Kasongo, A., additional, Belhachmi, J., additional, Izem, A., additional, Mdaghri, S., additional, El Khayate, S., additional, Zamd, M., additional, Medkouri, G., additional, Benghanem Gharbi, M., additional, and Ramdani, B., additional
- Published
- 2014
- Full Text
- View/download PDF
26. Transition épidémiologique en néphro-gériatrie
- Author
-
Zenasni, N., primary, Kanbouchi, F., additional, Izem, A., additional, El Khayate, S., additional, Zamd, M., additional, Medkouri, G., additional, Benghanem Gharbi, M., additional, and Ramdani, B., additional
- Published
- 2014
- Full Text
- View/download PDF
27. La néphropathie non diabétique chez les diabétiques biopsiés : prévalence et facteurs prédictifs
- Author
-
Zenasni, N., primary, Ouaddi, F., additional, Izem, A., additional, El Khayate, S., additional, Zamd, M., additional, Medkouri, G., additional, Benghanem Gharbi, M., additional, and Ramdani, B., additional
- Published
- 2014
- Full Text
- View/download PDF
28. Obesity and kidney disease: Hidden consequences of the epidemic
- Author
-
Kovesdy, C. P., Furth, S., Zoccali, C., Li, P. K. T., Guillermo Garcia Garcia, Benghanem-Gharbi, M., Boltaert, R., Dupuis, S., Erte, T., Kalantar-Zadeh, K., Osafo, C., Riella, M. C., and Zakharova, E.
29. Obesity and kidney disease: Hidden consequences of the epidemic,Obesidad y enfermedad renal: Consecuencias ocultas de la epidemia
- Author
-
Kovesdy, C. P., Furth, S., Zoccali, C., Tao Li, P. K., García-García, G., Benghanem-Gharbi, M., Bollaert, R., Dupuis, S., Erk, T., Kalantar-Zadeh, K., Kovesdy, C., Osafo, C., Riella, M. C., and Elena Zakharova
30. Availability, coverage, and scope of health information systems for kidney care across world countries and regions.
- Author
-
See EJ, Bello AK, Levin A, Lunney M, Osman MA, Ye F, Ashuntantang GE, Bellorin-Font E, Benghanem Gharbi M, Davison S, Ghnaimat M, Harden P, Htay H, Jha V, Kalantar-Zadeh K, Kerr PG, Klarenbach S, Kovesdy CP, Luyckx V, Neuen B, O'Donoghue D, Ossareh S, Perl J, Rashid HU, Rondeau E, Syed S, Sola L, Tchokhonelidze I, Tesar V, Tungsanga K, Kazancioglu RT, Wang AY, Yang CW, Zemchenkov A, Zhao MH, Jager KJ, Caskey F, Perkovic V, Jindal KK, Okpechi IG, Tonelli M, Feehally J, Harris DC, and Johnson DW
- Subjects
- Cross-Sectional Studies, Developing Countries, Humans, Kidney, Health Information Systems, Renal Insufficiency, Chronic epidemiology, Renal Insufficiency, Chronic therapy
- Abstract
Background: Health information systems (HIS) are fundamental tools for the surveillance of health services, estimation of disease burden and prioritization of health resources. Several gaps in the availability of HIS for kidney disease were highlighted by the first iteration of the Global Kidney Health Atlas., Methods: As part of its second iteration, the International Society of Nephrology conducted a cross-sectional global survey between July and October 2018 to explore the coverage and scope of HIS for kidney disease, with a focus on kidney replacement therapy (KRT)., Results: Out of a total of 182 invited countries, 154 countries responded to questions on HIS (85% response rate). KRT registries were available in almost all high-income countries, but few low-income countries, while registries for non-dialysis chronic kidney disease (CKD) or acute kidney injury (AKI) were rare. Registries in high-income countries tended to be national, in contrast to registries in low-income countries, which often operated at local or regional levels. Although cause of end-stage kidney disease, modality of KRT and source of kidney transplant donors were frequently reported, few countries collected data on patient-reported outcome measures and only half of low-income countries recorded process-based measures. Almost no countries had programs to detect AKI and practices to identify CKD-targeted individuals with diabetes, hypertension and cardiovascular disease, rather than members of high-risk ethnic groups., Conclusions: These findings confirm significant heterogeneity in the global availability of HIS for kidney disease and highlight important gaps in their coverage and scope, especially in low-income countries and across the domains of AKI, non-dialysis CKD, patient-reported outcomes, process-based measures and quality indicators for KRT service delivery., (© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
31. COVID-19: Patient care after discharge from the Intensive Care Unit.
- Author
-
Chadli A, Haraj NE, El Aziz S, Laidi S, Mounir A, Bensbaa S, Mjabber A, Barrou L, El Kettani El Hamidi C, Nsiri A, Al Harrar R, Ezzouine H, Charra B, Kamal N, Soussi Abdallaoui M, Bennouna GM, Marhoum El Filali K, Mchichi Alami K, Agoub M, El Mdaghri N, Ramdani B, Benghanem Gharbi M, and Afif MH
- Subjects
- Critical Care, Humans, Hydroxychloroquine, Intensive Care Units, Middle Aged, Patient Discharge, SARS-CoV-2, COVID-19
- Abstract
Introduction: The Ibn Rochd CHU is a tertiary care structure that provides care for the most severe cases of COVID-19 requiring hospitalisation in intensive care. The objective of study is to describe the complementary medical and psychological care of patients with COVID-19 in the endocrinology department after a stay in intensive care., Patients and Methods: This is a descriptive observational study of patients transferred from the intensive care unit to the endocrinology service following a COVID-19 infection during the period from 17 April 2020 to May 26, 2020. Clinical characteristics of the patients and complications related to COVID-19 infection were studied; a nutritional assessment using the MNA nutritional status assessment questionnaire; psychological assessment using quality-of-life questionnaires (Hamilton depression and anxiety, HAD, SF36, PCLS); a treatment satisfaction questionnaire (TQCMII) and an assessment of patient autonomy by the ADL score., Result: Our study included 41 patients with an average age of 55 years (19-85 years), a sex ratio M/F of 1.05, 43.9% were diabetic, 34.1% hypertensive, 4.9% asthmatic and 5% obese, and 51.2% were severe and critical cases. The average ICU stay is 8.42 days, requiring intubation in 12.2% of cases. All patients were treated with the Hydroxychloroquine, Azithromycin, vitamin C, zinc and corticosteroid protocol, 14.6% had undernutrition and 65.9% had a risk of undernutrition. The average BMI was 25.34 kg/m
2 (17-42), 61% had experienced weight loss, which was greater than 8 kg in 26.1% of cases, 12.2% of patients were not autonomous, 12.2% had moderate depression, 2.4% severe depression, 14.6% mild to moderate anxiety, 12.2% severe anxiety and 29.3% suffered acute post-traumatic stress disorder., Conclusion: Patients with COVID-19 are, in addition to the complications from coronavirus infection, vulnerable to undernutrition, psychological and motor complications. Additional care before discharge is essential for better integration of patients into their families., (© 2021 John Wiley & Sons Ltd.)- Published
- 2021
- Full Text
- View/download PDF
32. Design and implementation of the European-Mediterranean Postgraduate Programme on Organ Donation and Transplantation (EMPODaT) for Middle East/North Africa countries.
- Author
-
Ballesté C, Valero R, Istrate M, Peralta P, Mosharafa AA, Morsy AA, Bakr MA, Kamal Abdelkader AI, Sheashaa H, Juvelekian GS, Khachab M, Ahdab R, Faour W, Tahiri Jouti N, Benghanem Gharbi M, Bayahia R, Dakka T, Desatnik P, Jambou P, Pisarski P, Samson-Himmelstjerna P, Lücking KM, and Manyalich M
- Subjects
- Africa, Northern, Humans, Middle East, Prospective Studies, Organ Transplantation, Tissue and Organ Procurement
- Abstract
This prospective study reports the design and results obtained after the EMPODaT project implementation. This project was funded by the Tempus programme of the European Commission with the objective to implement a common postgraduate programme on organ donation and transplantation (ODT) in six selected universities from Middle East/North Africa (MENA) countries (Egypt, Lebanon and Morocco). The consortium, coordinated by the University of Barcelona, included universities from Spain, Germany, Sweden and France. The first phase of the project was to perform an analysis of the current situation in the beneficiary countries, including existing training programmes on ODT, Internet connection, digital facilities and competences, training needs, and ODT activity and accreditation requirements. A total of 90 healthcare postgraduate students participated in the 1-year training programme (30 ECTS academic credits). The methodology was based on e-learning modules and face-to-face courses in English and French. Training activities were evaluated through pre- and post-tests, self-assessment activities and evaluation charts. Quality was assessed through questionnaires and semi-structured interviews. The project results on a reproducible and innovative international postgraduate programme, improvement of knowledge, satisfaction of the participants and confirms the need on professionalizing the activity as the cornerstone to ensure organ transplantation self-sufficiency in MENA countries., (© 2021 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT.)
- Published
- 2021
- Full Text
- View/download PDF
33. Current status of health systems financing and oversight for end-stage kidney disease care: a cross-sectional global survey.
- Author
-
Yeung E, Bello AK, Levin A, Lunney M, Osman MA, Ye F, Ashuntantang G, Bellorin-Font E, Benghanem Gharbi M, Davison S, Ghnaimat M, Harden P, Jha V, Kalantar-Zadeh K, Kerr P, Klarenbach S, Kovesdy C, Luyckx V, Neuen B, O'Donoghue D, Ossareh S, Perl J, Ur Rashid H, Rondeau E, See E, Saad S, Sola L, Tchokhonelidze I, Tesar V, Tungsanga K, Turan Kazancioglu R, Wang AY, Wiebe N, Yang CW, Zemchenkov A, Zhao M, Jager KJ, Caskey F, Perkovic V, Jindal K, Okpechi IG, Tonelli M, Feehally J, Harris DC, and Johnson D
- Subjects
- Cross-Sectional Studies, Developing Countries, Health Services Accessibility, Humans, Kidney Failure, Chronic therapy, Renal Dialysis
- Abstract
Objectives: The Global Kidney Health Atlas (GKHA) is a multinational, cross-sectional survey designed to assess the current capacity for kidney care across all world regions. The 2017 GKHA involved 125 countries and identified significant gaps in oversight, funding and infrastructure to support care for patients with kidney disease, especially in lower-middle-income countries. Here, we report results from the survey for the second iteration of the GKHA conducted in 2018, which included specific questions about health financing and oversight of end-stage kidney disease (ESKD) care worldwide., Setting: A cross-sectional global survey., Participants: Key stakeholders from 182 countries were invited to participate. Of those, stakeholders from 160 countries participated and were included., Primary Outcomes: Primary outcomes included cost of kidney replacement therapy (KRT), funding for dialysis and transplantation, funding for conservative kidney management, extent of universal health coverage, out-of-pocket costs for KRT, within-country variability in ESKD care delivery and oversight systems for ESKD care. Outcomes were determined from a combination of desk research and input from key stakeholders in participating countries., Results: 160 countries (covering 98% of the world's population) responded to the survey. Economic factors were identified as the top barrier to optimal ESKD care in 99 countries (64%). Full public funding for KRT was more common than for conservative kidney management (43% vs 28%). Among countries that provided at least some public coverage for KRT, 75% covered all citizens. Within-country variation in ESKD care delivery was reported in 40% of countries. Oversight of ESKD care was present in all high-income countries but was absent in 13% of low-income, 3% of lower-middle-income, and 10% of upper-middle-income countries., Conclusion: Significant gaps and variability exist in the public funding and oversight of ESKD care in many countries, particularly for those in low-income and lower-middle-income countries., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
34. International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Africa.
- Author
-
Oguejiofor F, Kiggundu DS, Bello AK, Swanepoel CR, Ashuntantang G, Jha V, Harris DCH, Levin A, Tonelli M, Niang A, Wearne N, Moloi MW, Ulasi I, Arogundade FA, Saad S, Zaidi D, Osman MA, Ye F, Lunney M, Olanrewaju TO, Ekrikpo U, Umeizudike TI, Abdu A, Nalado AM, Makusidi MA, Liman HM, Sakajiki A, Diongole HM, Khan M, Benghanem Gharbi M, Johnson DW, and Okpechi IG
- Abstract
Despite positive economic forecasts, stable democracies, and reduced regional conflicts since the turn of the century, Africa continues to be afflicted by poverty, poor infrastructure, and a massive burden of communicable diseases such as HIV, malaria, tuberculosis, and diarrheal illnesses. With the rising prevalence of chronic kidney disease and kidney failure worldwide, these factors continue to hinder the ability to provide kidney care for millions of people on the continent. The International Society of Nephrology Global Kidney Health Atlas project was established to assess the global burden of kidney disease and measure global capacity for kidney replacement therapy (dialysis and kidney transplantation). The aim of this second iteration of the International Society of Nephrology Global Kidney Health Atlas was to evaluate the availability, accessibility, affordability, and quality of kidney care worldwide. We identified several gaps regarding kidney care in Africa, chief of which are (i) severe workforce limitations, especially in terms of the number of nephrologists; (ii) low government funding for kidney care; (iii) limited availability, accessibility, reporting, and quality of provided kidney replacement therapy; and (iv) weak national strategies and advocacy for kidney disease. We also identified that within Africa, the availability and accessibility to kidney replacement therapy vary significantly, with North African countries faring far better than sub-Sahara African countries. The evidence suggests an urgent need to increase the workforce and government funding for kidney care, collect adequate information on the burden of kidney disease from African countries, and develop and implement strategies to enhance disease prevention and control across the continent., (© 2021 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
35. Availability, Accessibility, and Quality of Conservative Kidney Management Worldwide.
- Author
-
Lunney M, Bello AK, Levin A, Tam-Tham H, Thomas C, Osman MA, Ye F, Bellorin-Font E, Benghanem Gharbi M, Ghnaimat M, Htay H, Cho Y, Jha V, Ossareh S, Rondeau E, Sola L, Tchokhonelidze I, Tesar V, Tungsanga K, Kazancioglu RT, Wang AY, Yang CW, Zemchenkov A, Zhao MH, Jager KJ, Jindal KK, Okpechi IG, Brown EA, Brown M, Tonelli M, Harris DC, Johnson DW, Caskey FJ, and Davison SN
- Subjects
- Decision Making, Shared, Humans, Internationality, Patient Care Team statistics & numerical data, Religion, Social Support, Surveys and Questionnaires, Conservative Treatment standards, Developed Countries statistics & numerical data, Developing Countries statistics & numerical data, Health Services Accessibility statistics & numerical data, Kidney Failure, Chronic therapy, Quality of Health Care
- Abstract
Background and Objectives: People with kidney failure typically receive KRT in the form of dialysis or transplantation. However, studies have suggested that not all patients with kidney failure are best suited for KRT. Additionally, KRT is costly and not always accessible in resource-restricted settings. Conservative kidney management is an alternate kidney failure therapy that focuses on symptom management, psychologic health, spiritual care, and family and social support. Despite the importance of conservative kidney management in kidney failure care, several barriers exist that affect its uptake and quality., Design, Setting, Participants, & Measurements: The Global Kidney Health Atlas is an ongoing initiative of the International Society of Nephrology that aims to monitor and evaluate the status of global kidney care worldwide. This study reports on findings from the 2018 Global Kidney Health Atlas survey, specifically addressing the availability, accessibility, and quality of conservative kidney management., Results: Respondents from 160 countries completed the survey, and 154 answered questions pertaining to conservative kidney management. Of these, 124 (81%) stated that conservative kidney management was available. Accessibility was low worldwide, particularly in low-income countries. Less than half of countries utilized multidisciplinary teams (46%); utilized shared decision making (32%); or provided psychologic, cultural, or spiritual support (36%). One-quarter provided relevant health care providers with training on conservative kidney management delivery., Conclusions: Overall, conservative kidney management is available in most countries; however, it is not optimally accessible or of the highest quality., (Copyright © 2021 by the American Society of Nephrology.)
- Published
- 2020
- Full Text
- View/download PDF
36. Global overview of health systems oversight and financing for kidney care.
- Author
-
Bello AK, Alrukhaimi M, Ashuntantang GE, Bellorin-Font E, Benghanem Gharbi M, Braam B, Feehally J, Harris DC, Jha V, Jindal K, Johnson DW, Kalantar-Zadeh K, Kazancioglu R, Kerr PG, Lunney M, Olanrewaju TO, Osman MA, Perl J, Rashid HU, Rateb A, Rondeau E, Sakajiki AM, Samimi A, Sola L, Tchokhonelidze I, Wiebe N, Yang CW, Ye F, Zemchenkov A, Zhao MH, and Levin A
- Abstract
Reliable governance and health financing are critical to the abilities of health systems in different countries to sustainably meet the health needs of their peoples, including those with kidney disease. A comprehensive understanding of existing systems and infrastructure is therefore necessary to globally identify gaps in kidney care and prioritize areas for improvement. This multinational, cross-sectional survey, conducted by the ISN as part of the Global Kidney Health Atlas, examined the oversight, financing, and perceived quality of infrastructure for kidney care across the world. Overall, 125 countries, comprising 93% of the world's population, responded to the entire survey, with 122 countries responding to questions pertaining to this domain. National oversight of kidney care was most common in high-income countries while individual hospital oversight was most common in low-income countries. Parts of Africa and the Middle East appeared to have no organized oversight system. The proportion of countries in which health care system coverage for people with kidney disease was publicly funded and free varied for AKI (56%), nondialysis chronic kidney disease (40%), dialysis (63%), and kidney transplantation (57%), but was much less common in lower income countries, particularly Africa and Southeast Asia, which relied more heavily on private funding with out-of-pocket expenses for patients. Early detection and management of kidney disease were least likely to be covered by funding models. The perceived quality of health infrastructure supporting AKI and chronic kidney disease care was rated poor to extremely poor in none of the high-income countries but was rated poor to extremely poor in over 40% of low-income countries, particularly Africa. This study demonstrated significant gaps in oversight, funding, and infrastructure supporting health services caring for patients with kidney disease, especially in low- and middle-income countries.
- Published
- 2018
- Full Text
- View/download PDF
37. Global access of patients with kidney disease to health technologies and medications: findings from the Global Kidney Health Atlas project.
- Author
-
Htay H, Alrukhaimi M, Ashuntantang GE, Bello AK, Bellorin-Font E, Benghanem Gharbi M, Braam B, Feehally J, Harris DC, Jha V, Jindal K, Kalantar-Zadeh K, Kazancioglu R, Kerr PG, Levin A, Lunney M, Okpechi IG, Olah ME, Olanrewaju TO, Osman MA, Parpia Y, Perl J, Qarni B, Rashid HU, Rateb A, Rondeau E, Salako BL, Sola L, Tchokhonelidze I, Tonelli M, Wiebe N, Wirzba I, Yang CW, Ye F, Zemchenkov A, Zhao MH, and Johnson DW
- Abstract
Access to essential medications and health products is critical to effective management of kidney disease. Using data from the ISN Global Kidney Health Atlas multinational cross-sectional survey, global access of patients with kidney disease to essential medications and health products was examined. Overall, 125 countries participated, with 118 countries, composing 91.5% of the world's population, providing data on this domain. Most countries were unable to access eGFR and albuminuria in their primary care settings. Only one-third of low-income countries (LICs) were able to measure serum creatinine and none were able to access eGFR or quantify proteinuria. The ability to monitor diabetes mellitus through serum glucose and glycated hemoglobin measurements was suboptimal. Pathology services were rarely available in tertiary care in LICs (12%) and lower middle-income countries (45%). While acute and chronic hemodialysis services were available in almost all countries, acute and chronic peritoneal dialysis services were rarely available in LICs (18% and 29%, respectively). Kidney transplantation was available in 79% of countries overall and in 12% of LICs. While over one-half of all countries publicly funded RRT and kidney medications with or without copayment, this was less common in LICs and lower middle-income countries. In conclusion, this study demonstrated significant gaps in services for kidney care and funding that were most apparent in LICs and lower middle-income countries.
- Published
- 2018
- Full Text
- View/download PDF
38. Guidelines, policies, and barriers to kidney care: findings from a global survey.
- Author
-
Lunney M, Alrukhaimi M, Ashuntantang GE, Bello AK, Bellorin-Font E, Benghanem Gharbi M, Jha V, Johnson DW, Kalantar-Zadeh K, Kazancioglu R, Olah ME, Olanrewaju TO, Osman MA, Parpia Y, Perl J, Rashid HU, Rateb A, Rondeau E, Sola L, Tchokhonelidze I, Tonelli M, Wiebe N, Wirzba I, Yang CW, Ye F, Zemchenkov A, Zhao MH, and Levin A
- Abstract
An international survey led by the International Society of Nephrology in 2016 assessed the current capacity of kidney care worldwide. To better understand how governance and leadership guide kidney care, items pertinent to government priority, advocacy, and guidelines, among others, were examined. Of the 116 responding countries, 36% ( n = 42) reported CKD as a government health care priority, which was associated with having an advocacy group (χ2 = 11.57; P = 0.001). Nearly one-half (42%; 49 of 116) of countries reported an advocacy group for CKD, compared with only 19% (21 of 112) for AKI. Over one-half (59%; 68 of 116) of countries had a noncommunicable disease strategy. Similarly, 44% (48 of 109), 55% (57 of 104), and 47% (47 of 101) of countries had a strategy for nondialysis CKD, chronic dialysis, and kidney transplantation, respectively. Nearly one-half (49%; 57 of 116) reported a strategy for AKI. Most countries (79%; 92 of 116) had access to CKD guidelines and just over one-half (53%; 61 of 116) reported guidelines for AKI. Awareness and adoption of guidelines were low among nonnephrologist physicians. Identified barriers to kidney care were factors related to patients, such as knowledge and attitude (91%; 100 of 110), physicians (84%; 92 of 110), and geography (74%; 81 of 110). Specific to renal replacement therapy, patients and geography were similarly identified as a barrier in 78% (90 of 116) and 71% (82 of 116) of countries, respectively, with the addition of nephrologists (72%; 83 of 116) and the health care system (73%; 85 of 116). These findings inform how kidney care is currently governed globally. Ensuring that guidelines are feasible and distributed appropriately is important to enhancing their adoption, particularly in primary care. Furthermore, increasing advocacy and government priority, especially for AKI, may increase awareness and strategies to better guide kidney care.
- Published
- 2018
- Full Text
- View/download PDF
39. Global capacity for clinical research in nephrology: a survey by the International Society of Nephrology.
- Author
-
Okpechi IG, Alrukhaimi M, Ashuntantang GE, Bellorin-Font E, Benghanem Gharbi M, Braam B, Feehally J, Harris DC, Jha V, Jindal K, Johnson DW, Kalantar-Zadeh K, Kazancioglu R, Levin A, Lunney M, Olanrewaju TO, Perkovic V, Perl J, Rashid HU, Rondeau E, Salako BL, Samimi A, Sola L, Tchokhonelidze I, Wiebe N, Yang CW, Ye F, Zemchenkov A, Zhao MH, and Bello AK
- Abstract
Due to the worldwide rising prevalence of chronic kidney disease (CKD), there is a need to develop strategies through well-designed clinical studies to guide decision making and improve delivery of care to CKD patients. A cross-sectional survey was conducted based on the International Society of Nephrology Global Kidney Health Atlas data. For this study, the survey assessed the capacity of various countries and world regions in participating in and conducting kidney research. Availability of national funding for clinical trials was low (27%, n = 31), with the lowest figures obtained from Africa (7%, n = 2) and South Asia (0%), whereas high-income countries in North America and Europe had the highest participation in clinical trials. Overall, formal training to conduct clinical trials was inadequate for physicians (46%, n = 53) and even lower for nonphysicians, research assistants, and associates in clinical trials (34%, n = 39). There was also diminished availability of workforce and funding to conduct observational cohort studies in nephrology, and participation in highly specialized transplant trials was low in many regions. Overall, the availability of infrastructure (bio-banking and facilities for storage of clinical trial medications) was low, and it was lowest in low-income and lower-middle-income countries. Ethics approval for study conduct was mandatory in 91% ( n = 106) of countries and regions, and 62% ( n = 66) were reported to have institutional committees. Challenges with obtaining timely approval for a study were reported in 53% ( n = 61) of regions but the challenges were similar across these regions. A potential limitation is the possibility of over-reporting or under-reporting due to social desirability bias. This study highlights some of the major challenges for participating in and conducting kidney research and offers suggestions for improving global kidney research.
- Published
- 2018
- Full Text
- View/download PDF
40. Global coverage of health information systems for kidney disease: availability, challenges, and opportunities for development.
- Author
-
See EJ, Alrukhaimi M, Ashuntantang GE, Bello AK, Bellorin-Font E, Benghanem Gharbi M, Braam B, Feehally J, Harris DC, Jha V, Jindal K, Kalantar-Zadeh K, Kazancioglu R, Levin A, Lunney M, Okpechi IG, Olanrewaju TO, Osman MA, Perl J, Qarni B, Rashid HU, Rateb A, Rondeau E, Samimi A, Sikosana MLN, Sola L, Tchokhonelidze I, Wiebe N, Yang CW, Ye F, Zemchenkov A, Zhao MH, and Johnson DW
- Abstract
Development and planning of health care services requires robust health information systems to define the burden of disease, inform policy development, and identify opportunities to improve service provision. The global coverage of kidney disease health information systems has not been well reported, despite their potential to enhance care. As part of the Global Kidney Health Atlas, a cross-sectional survey conducted by the International Society of Nephrology, data were collected from 117 United Nations member states on the coverage and scope of kidney disease health information systems and surveillance practices. Dialysis and transplant registries were more common in high-income countries. Few countries reported having nondialysis chronic kidney disease and acute kidney injury registries. Although 62% of countries overall could estimate their prevalence of chronic kidney disease, less than 24% of low-income countries had access to the same data. Almost all countries offered chronic kidney disease testing to patients with diabetes and hypertension, but few to high-risk ethnic groups. Two-thirds of countries were unable to determine their burden of acute kidney injury. Given the substantial heterogeneity in the availability of health information systems, especially in low-income countries and across nondialysis chronic kidney disease and acute kidney injury, a global framework for prioritizing development of these systems in areas of greatest need is warranted.
- Published
- 2018
- Full Text
- View/download PDF
41. Global nephrology workforce: gaps and opportunities toward a sustainable kidney care system.
- Author
-
Osman MA, Alrukhaimi M, Ashuntantang GE, Bellorin-Font E, Benghanem Gharbi M, Braam B, Courtney M, Feehally J, Harris DC, Jha V, Jindal K, Johnson DW, Kalantar-Zadeh K, Kazancioglu R, Klarenbach S, Levin A, Lunney M, Okpechi IG, Olanrewaju TO, Perl J, Rashid HU, Rondeau E, Salako BL, Samimi A, Sola L, Tchokhonelidze I, Wiebe N, Yang CW, Ye F, Zemchenkov A, Zhao MH, and Bello AK
- Abstract
The health workforce is the cornerstone of any health care system. An adequately trained and sufficiently staffed workforce is essential to reach universal health coverage. In particular, a nephrology workforce is critical to meet the growing worldwide burden of kidney disease. Despite some attempts, the global nephrology workforce and training capacity remains widely unknown. This multinational cross-sectional survey was part of the Global Kidney Health Atlas project, a new initiative administered by the International Society of Nephrology (ISN). The objective of this study was to address the existing global nephrology workforce and training capacity. The questionnaire was administered online, and all data were analyzed and presented by ISN regions and World Bank country classification. Overall, 125 United Nations member states responded to the entire survey, with 121 countries responding to survey questions pertaining to the nephrology workforce. The global nephrologist density was 8.83 per million population (PMP); high-income countries reported a nephrologist density of 28.52 PMP compared with 0.31 PMP in low-income countries. Similarly, the global nephrologist trainee density was 1.87 PMP; high-income countries reported a 30 times greater nephrology trainee density than low-income countries (6.03 PMP vs. 0.18 PMP). Countries reported a shortage in all care providers in nephrology. A nephrology training program existed in 79% of countries, ranging from 97% in high-income countries to 41% in low-income countries. In countries with a training program, the majority (86%) of programs were 2 to 4 years, and the most common training structure (56%) was following general internal medicine. We found significant variation in the global density of nephrologists and nephrology trainees and shortages in all care providers in nephrology; the gap was more prominent in low-income countries, particularly in African and South Asian ISN regions. These findings point to significant gaps in the current nephrology workforce and opportunities for countries and regions to develop and maintain a sustainable workforce.
- Published
- 2018
- Full Text
- View/download PDF
42. Action plan for optimizing the design of clinical trials in chronic kidney disease.
- Author
-
Perkovic V, Craig JC, Chailimpamontree W, Fox CS, Garcia-Garcia G, Benghanem Gharbi M, Jardine MJ, Okpechi IG, Pannu N, Stengel B, Tuttle KR, Uhlig K, and Levey AS
- Abstract
High-quality clinical trials are the cornerstone of evidence-based prevention and treatment of a disease, but nephrology has a strikingly weak base of such trials. Building the evidence base to improve outcomes for people with a kidney disease, therefore, requires both greater quantity and quality of clinical trials. To address these issues, we propose that we aim to enroll 30% of people with chronic kidney disease in trials by 2030. Goal 1: Strongly encourage and promote the conduct of clinical trials in people with chronic kidney disease to increase the number of clinical trials conducted. Goal 2: Optimize the design of clinical trials in people with chronic kidney disease. Goal 3: Increase the capacity for conducting clinical trials in people with chronic kidney disease.
- Published
- 2017
- Full Text
- View/download PDF
43. Control of blood pressure and cardiovascular risk in Moroccan patients with newly diagnosed hypertension: a 3-month observational study in primary care.
- Author
-
Alami M, El Hattaoui M, Seqat M, Sadik J, Aouad A, and Benghanem Gharbi M
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Hypertension epidemiology, Incidence, Male, Middle Aged, Morocco epidemiology, Prospective Studies, Risk Factors, Time Factors, Young Adult, Blood Pressure physiology, Blood Pressure Monitoring, Ambulatory methods, Hypertension physiopathology, Primary Health Care
- Abstract
Background: Control of blood pressure and reduction of cardiovascular risk factors are mandatory in patients with hypertension. The aim of this study was to determine the proportion of patients with controlled hypertension and to describe the cardiovascular risk profile in hypertensive patients followed by general practitioners (GPs) in Morocco., Methods: This national, observational, multicentre, prospective, longitudinal study of patients with newly diagnosed hypertension was carried out between September 2011 and December 2011. The use of antihypertensive drugs was evaluated at inclusion and after 3 months of follow up. Uncontrolled hypertension was defined as systolic blood pressure (SBP) ⩾ 140 mmHg or diastolic blood pressure (DBP) ⩾ 90 mmHg at 3 months of follow up. The SCORE scale issued by the European Society of Cardiology (ESC) was used to assess overall cardiovascular risk and probability of experiencing a cardiovascular event within 10 years., Results: A total of 909 hypertensive patients were recruited (62.4% female). Mean age was 56.8 ± 10.6 years. More than half of the patients (53.0%) were between 40-60 years and more than one-third (34.1%) were obese [body mass index (BMI) ⩾ 30 kg/m
2 ]. There were significantly more obese females than males ( p < 0.001). Over half of the patients (52.5%) had a high or extremely high cardiovascular risk. Abdominal obesity (measured as waist circumference) was the most common cardiovascular risk factor (61.7%) followed by age (40.5%), dyslipidaemia (36.3%) and diabetes (34.3%). Mean SBP decreased from 168.1 ± 14.8 to 138.3 ± 13.2 mmHg ( p < 0.001) and mean DBP decreased from 93.0 ± 10.5 to 81.0 ± 8.6 mmHg ( p < 0.001) after 3 months of treatment. Control of blood pressure was achieved in only 46.8% of patients. Poor compliance (17.1%) and a lack of treatment efficacy (16.9%) were the two main reasons for not achieving the blood pressure target., Conclusions: More than half (53.2%) of the hypertensive patients in our study did not achieve adequate blood pressure control during the 3-month follow-up period and had a high cardiovascular risk. More effective management of hypertension is required in primary care.- Published
- 2017
- Full Text
- View/download PDF
44. Chronic kidney disease, hypertension, diabetes, and obesity in the adult population of Morocco: how to avoid "over"- and "under"-diagnosis of CKD.
- Author
-
Benghanem Gharbi M, Elseviers M, Zamd M, Belghiti Alaoui A, Benahadi N, Trabelssi el H, Bayahia R, Ramdani B, and De Broe ME
- Subjects
- Adult, Age Factors, Aged, Arabs, Blood Glucose analysis, Creatinine blood, Cross-Sectional Studies, Diabetes Mellitus blood, Diabetes Mellitus urine, Female, Hematuria diagnosis, Hematuria epidemiology, Humans, Hypertension blood, Hypertension urine, Male, Middle Aged, Morocco epidemiology, Obesity blood, Obesity urine, Prevalence, Proteinuria diagnosis, Proteinuria epidemiology, Random Allocation, Renal Insufficiency, Chronic blood, Renal Insufficiency, Chronic urine, Risk Factors, Sex Factors, Diabetes Mellitus epidemiology, Glomerular Filtration Rate, Hypertension epidemiology, Obesity epidemiology, Renal Insufficiency, Chronic diagnosis, Renal Insufficiency, Chronic epidemiology
- Abstract
The prevalence of hypertension, diabetes, obesity, and chronic kidney disease (CKD) in an adult Arabic-Berber population was investigated according to 2012 KDIGO guidelines. A stratified, randomized, representative sample of 10,524 participants was obtained. Weight, height, blood pressure, proteinuria (dipstick), plasma creatinine, estimated glomerular filtration rate, and fasting glycemia were measured. Abnormal results were controlled within 2 weeks; eGFR was retested at 3, 6, and 12 months. The population adjusted prevalences were 16.7% hypertension, 23.2% obesity, 13.8% glycemia, 1.6% for eGFR under 60 ml/min/1.73 m(2) and confirmed proteinuria 1.9% and hematuria 3.4%. Adjusted prevalence of CKD was 5.1%; distribution over KDIGO stages: CKD1: 17.8%; CKD2: 17.2%; CKD3: 52.5% (3A: 40.2%; 3B: 12.3%); CKD4: 4.4%; CKD5: 7.2%. An eGFR distribution within the sex and age categories was constructed using the third percentile as threshold for decreased eGFR. A single threshold (under 60 ml/min/1.73 m(2)) eGFR classifying CKD3-5 leads to "overdiagnosis" of CKD3A in the elderly, overt "underdiagnosis" in younger individuals with eGFR over 60 ml/min/1.73 m(2), below the third percentile, and no proteinuria. By using the KDIGO guidelines in a correct way, "kidney damage" (confirmed proteinuria, hematuria) and the demonstration of chronicity of decreased eGFR <60 ml/min/1.73 m(2), combined with the third percentile as a cutoff for the normality of eGFR for age and sex, overcome false positives and negatives, substantially decrease CKD3A prevalence, and greatly increase the accuracy of identifying CKD., (Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
45. A renal registry for Africa: first steps.
- Author
-
Davids MR, Eastwood JB, Selwood NH, Arogundade FA, Ashuntantang G, Benghanem Gharbi M, Jarraya F, MacPhee IA, McCulloch M, Plange-Rhule J, Swanepoel CR, and Adu D
- Abstract
There is a dearth of data on end-stage renal disease (ESRD) in Africa. Several national renal registries have been established but have not been sustainable because of resource limitations. The African Association of Nephrology (AFRAN) and the African Paediatric Nephrology Association (AFPNA) recognize the importance of good registry data and plan to establish an African Renal Registry. This article reviews the elements needed for a successful renal registry and gives an overview of renal registries in developed and developing countries, with the emphasis on Africa. It then discusses the proposed African Renal Registry and the first steps towards its implementation. A registry requires a clear purpose, and agreement on inclusion and exclusion criteria, the dataset and the data dictionary. Ethical issues, data ownership and access, the dissemination of findings and funding must all be considered. Well-documented processes should guide data collection and ensure data quality. The ERA-EDTA Registry is the world's oldest renal registry. In Africa, registry data have been published mainly by North African countries, starting with Egypt and Tunisia in 1975. However, in recent years no African country has regularly reported national registry data. A shared renal registry would provide participating countries with a reliable technology platform and a common data dictionary to facilitate joint analyses and comparisons. In March 2015, AFRAN organized a registry workshop for African nephrologists and then took the decision to establish, for the first time, an African Renal Registry. In conclusion, African nephrologists have decided to establish a continental renal registry. This initiative could make a substantial impact on the practice of nephrology and the provision of services for adults and children with ESRD in many African countries.
- Published
- 2016
- Full Text
- View/download PDF
46. [Management of iodine-131 ablation therapy for thyroid carcinoma in a patient on chronic hemodialysis].
- Author
-
Zenasni N, Elkhayat S, Taleb S, Zamd M, Medkouri G, Benghanem Gharbi M, Ramdani B, Aschawa H, and Guensi A
- Subjects
- Adult, Carcinoma, Papillary, Humans, Male, Radiotherapy Dosage, Thyroid Cancer, Papillary, Carcinoma radiotherapy, Iodine Radioisotopes therapeutic use, Kidney Failure, Chronic therapy, Peritoneal Dialysis, Continuous Ambulatory, Thyroid Neoplasms radiotherapy
- Abstract
Iodine-131 ablation therapy for thyroid cancer in the patient on chronic hemodialysis represents a real problem since the main route of elimination of radioiodine is urinary. There is no recommendation on the management of this treatment in the patient on hemodialysis. We report our experience of management of this treatment in a patient aged 38 years, undergoing hemodialysis for chronic renal failure, and who have been indicated the treatment with iodine-131 for papillary thyroid carcinoma high risk. After multidisciplinary discussions (nephrologists and specialists in nuclear medicine and radiation safety), it has been decided to treat the patient with continuous ambulatory peritoneal dialysis therapy (CAPD). Because of the low but continuous elimination of iodine in the case of CAPD, the patient received a reduced ablative (131)I dose of 1850 MBq, which is 30% of the usual dose delivered in subjects with normal renal function. The patient was hospitalized for four days in nuclear medicine unit and the (131)I radioactivity emitted from him was 2.5 μSv/h at one meter at his hospital discharge. In conclusion, CAPD in relay of hemodialysis is a technique of renal replacement therapy that can be suggested to minimize exposure to radioactivity to the patient, his family and the medical staff., (Copyright © 2015 Association Société de néphrologie. Published by Elsevier SAS. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
47. [Estimate of the needs in renal transplantation in Morocco].
- Author
-
Boly A, El Hassane Trabelsi M, Ramdani B, Bayahia R, Benghanem Gharbi M, Boucher S, El Berri H, Nejjari C, and Couchoud C
- Subjects
- Adolescent, Adult, Aged, Female, Forecasting, Humans, Kidney Failure, Chronic therapy, Male, Middle Aged, Morocco epidemiology, Registries, Renal Dialysis statistics & numerical data, Waiting Lists, Young Adult, Kidney Failure, Chronic epidemiology, Kidney Transplantation statistics & numerical data, Needs Assessment
- Abstract
Kidney transplantation is still underdeveloped in Morocco. In order to anticipate needs and discuss a possible reorganization of the provision of care, an estimate of the number of patients who would benefit from kidney transplant was conducted. This study was done in two steps. During the first step, based on the French renal replacement therapy registry (Rein), we develop a prediction score based on the likelihood of being treated by an autonomous dialysis (hemodialysis in self-care unit or peritoneal dialysis non-assisted by a nurse) and be registered on the national kidney transplant waiting list. During the second step, we apply this score to the data of the registry Magredial (Moroccan registry of renal replacement therapy, deployed in seven regions). Twelve parameters were related to autonomy and registration on the waiting list. Each of these parameters has been assigned a weight. Each patient was assigned a number of points, sum of different weights. By retaining a threshold of 21 points (80% specificity), 2260 subjects (57%) had a score less than or equal to this threshold in Magredial. With a number of patients on dialysis in Morocco estimated to 13,000 in late 2013, the estimated need for kidney transplant will be of 7410. This estimate should encourage professionals and health authorities of Morocco to engage more effort in the implementation of actions related to the transplant program., (Copyright © 2014 Association Société de néphrologie. Published by Elsevier SAS. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
48. Renal replacement therapies for end-stage renal disease in North Africa.
- Author
-
Benghanem Gharbi M
- Subjects
- Africa, Northern, Humans, Renal Dialysis, Kidney Failure, Chronic therapy, Kidney Transplantation
- Abstract
Despite population, social and cultural similarities between the countries in the region, large differences in the management of end-stage renal disease (ESRD) are found. This reflects the varying policies and health priorities of different countries, leading to differences in terms of renal replacement therapies (RRT) facilities. Hemodialysis remains the most frequent modality. Demographic and epidemiological transition has lead to an increased incidence of diabetes mellitus and arterial hypertension, but glomerulonephritis and interstitial nephropathies remain important causes of ESRD in the region.
- Published
- 2010
49. Prevention and transplantation in chronic kidney disease: what is achievable in emerging countries? Meeting report: Bamako meeting December 4-6, 2008.
- Author
-
Persy VP, Remuzzi G, Perico N, Benghanem Gharbi M, Adu D, Jha V, Rizvi A, Ben Ammar M, Fongoro S, and De Broe ME
- Subjects
- Humans, Kidney Transplantation ethnology, Mali, Renal Insufficiency, Chronic ethnology, Achievement, Developing Countries, Global Health, Kidney Transplantation trends, Renal Insufficiency, Chronic surgery
- Abstract
Experts from all continents discussed the present and future of nephrology and transplantation medicine in emerging countries during a 3-day conference, supported by the World Health Organization, the International Society of Nephrology, the Transplantation Society-Global Alliance for Transplantation and the Ministry of Health of the Republic of Mali. This conference was held in Bamako, Mali on December 4-6, 2008, and focused on prevention and treatment of chronic kidney disease in emerging countries. Apart from delivering high-quality medical and scientific knowledge, the meeting was mainly a call to action for emerging countries to start chronic kidney disease prevention and screening programs, develop end-stage renal disease registries and start or further elaborate transplantation programs. International as well as regional collaborations need to be stimulated and strengthened in order to allow emerging countries to acquire the information, technology, experience and skills necessary to achieve these ambitious goals., (Copyright 2010 S. Karger AG, Basel.)
- Published
- 2010
- Full Text
- View/download PDF
50. [Sexual dysfunction among 78 Moroccan male hemodialysis patients: clinical and endocrine study].
- Author
-
Zamd M, Farh M, Hbid O, Zabari M, Benghanem Gharbi M, Ramdani B, Zaïd D, El Abbadi N, Lalaoui K, Belhouari A, and Hassan Tahri E
- Subjects
- Adult, Erectile Dysfunction blood, Erectile Dysfunction epidemiology, Ferritins blood, Follicle Stimulating Hormone blood, Gynecomastia blood, Gynecomastia epidemiology, Humans, Iron Overload complications, Kidney Failure, Chronic complications, Luteinizing Hormone blood, Male, Middle Aged, Morocco, Parathyroid Hormone blood, Prolactin blood, Sexual Dysfunction, Physiological etiology, Surveys and Questionnaires, Testosterone blood, Zinc blood, Kidney Failure, Chronic therapy, Renal Dialysis adverse effects, Sexual Dysfunction, Physiological epidemiology
- Abstract
Purpose: To investigate the correlation between biochemical and endocrine variables with sexual disorders in 78 male patients on chronic hemodialysis at the Ibn Rochd University Hospital (Casablanca-Morocco)., Methods: Seventy-eight male hemodialysis patients with chronic renal failure were evaluated with regard to their sexual function. All patients answered a personal questionnaire on their sexual activity. Hormone (FSH, LH, prolactin, testosterone, and parathyroid hormone) and zinc and ferritin assays were also performed., Results: The men reported erection (44.9%), libido (44.9%), ejaculation (26.8%), and orgasm (21.8%) disorders. Gynecomastia was observed in 17.9% of the patients. There was no correlation with weight nor the nature of the causal nephropathy nor with duration of dialysis. Levels of gonadotropins (FSH, LH), prolactin, and parathyroid hormone were elevated. Testosterone levels were low. Ferritinemia was elevated but there was no significant variation in zincemia. There was a negative curvilinear relationship between serum testosterone and sexual disorders, and between gynecomastia and ferritinemia. LH and prolactin levels were positively correlated with gynecomastia., Conclusion: Abnormal hormonal and iron overload could be important factors involved in the complex pathogenesis of sexual dysfunction in chronic renal failure patients undergoning hemodialysis.
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.